Experts Recount the Most Notable Data From the 2026 Genitourinary Cancers Symposium

During the 2026 Genitourinary Cancers Symposium (ASCO GU), which was held from February 26 through 28, 2026, in San Francisco, California, experts in genitourinary cancer care from across the world convened to share new data in renal cell carcinoma (RCC), urothelial carcinoma, and prostate cancer. Notable presentations included data from the first interim analysis of the phase 3 LITESPARK-022 trial (NCT05239728), results from the final analysis of the SunRISE-2 study (NCT04658862), findings from the phase 3 KEYNOTE-B15/EV-304 trial (NCT04700124) and final data from the phase 3 EORTC 1333/PEACE-3 trial (NCT02194842).